Trials / Recruiting
RecruitingNCT06458439
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Conditions
- Lymphoma, Non-Hodgkin
- Relapsed Diffuse Large B Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epcoritamab | * C1D1: fixed priming dose of 0.16 mg subcutaneous injection * C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection * C1D15 onward: fixed full dose of 48 mg subcutaneous injection |
Timeline
- Start date
- 2024-09-24
- Primary completion
- 2027-10-01
- Completion
- 2027-12-01
- First posted
- 2024-06-13
- Last updated
- 2025-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06458439. Inclusion in this directory is not an endorsement.